Full Text View
Tabular View
No Study Results Posted
Related Studies
Epirubicin and Celecoxib in Treating Patients With Hepatocellular Carcinoma
This study is ongoing, but not recruiting participants.
Study NCT00057980   Information provided by National Cancer Institute (NCI)
First Received: April 7, 2003   Last Updated: January 24, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Liver Cancer
Additional conditions recognized in this trial
Carcinoma
Carcinoma, Hepatocellular
Liver Neoplasms
More general conditions related to this trial
Adenocarcinoma
Digestive System Diseases
Digestive System Neoplasms
Liver Diseases
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Interventions listed in this trial
celecoxib
epirubicin hydrochloride
Additional drug interventions recognized in this trial
Epirubicin
More general drug interventions related to this trial
Analgesics
Analgesics, Non-Narcotic
Anti-Inflammatory Agents
Anti-Inflammatory Agents, Non-Steroidal
Antibiotics, Antineoplastic
Antineoplastic Agents
Antirheumatic Agents
Central Nervous System Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses
Sponsors listed in this trial
Robert H. Lurie Cancer Center
National Cancer Institute (NCI)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services